The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Treating TP53 mutant mantle cell lymphoma in the BOVen trial
Patients with TP53 mutant mantle cell lymphoma (MCL) represent an unmet need and there care no current frontline standard of care for these high risk patients. Anita Kumar, MD, Memorial Sloan Kettering, Short Hills, NJ, presents results from the Phase II BOVen trial (NCT03824483), which investigated zanubrutinib, obinutuzumab, and venetoclax in patients with TP53 mutant MCL. Two cycles of zanubrutinib and obinutuzumab were initially administered, followed by venetoclax. The regimen was well tolerated and displayed preliminary efficacy, with a majority of patients being in ongoing remission. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
